The UK NCRI AML19 trial randomized 189 younger adults (median age 56) with newly diagnosed adverse cytogenetic AML or high-risk MDS to receive either CPX-351 or FLAG-Ida. The gene discussed is IDUA; the disease is acute myeloid leukemia.